Insights

Mayne Pharma (ASX:MYX) share price drops on class action

The pharmaceutical company is the subject of legal proceedings.
The post Mayne Pharma (ASX:MYX) share price drops on class action appeared first on The Motley Fool Australia. –

The Mayne Pharma Group Ltd (ASX: MYX) share price is struggling to catch a bid in today’s session.

Shares in the pharmaceutical company are struggling after the company announced it is facing a class action.

Here’s what the company announced and why investors are exercising caution over the Mayne share price.  

Mayne share price dips on proceeding of class action

Earlier today, Mayne announced that the company has been slapped with an investor class action.

According to the announcement, legal proceedings have been lodged in the Supreme Court of Victoria.

Mayne noted the class action alleged the company undertook misleading or deceptive conduct. In addition, the action alleges the company was in breach of continuous disclosure obligations over alleged anti-competitive conduct in the United States.

Australian law firm Phi Finney McDonald brought the legal proceedings. The law firm is acting on behalf of all investors who acquired shares in Mayne between 24 November 2014 and 15 December 2016.

In the company’s announcement, Mayne emphatically denies any and all allegations of wrongdoing. Accordingly, the company noted it will vigorously defend the proceedings.

More on the class action against Mayne

According to the website of Phi Finney McDonald, it is alleged Mayne participated in a conspiracy to restrain trade, inflate the price of generic pharmaceuticals, and reduce competition.

The class action against Mayne follows an announcement on 15 December 2016. On that day, the Attorney General of Connecticut commenced anti-trust civil proceedings against a number of pharmaceutical companies, including Mayne Pharma Inc (US).

There are 3 main allegations against Mayne Pharma. In particular, it’s alleged the company agreed to price-fixing and market-sharing arrangements from late 2014.

Snapshot of the Mayne share price

Mayne Pharma is a specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals. The company also provides contract development and manufacturing services to clients. Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA.  

Despite soaring to a 52-week-high in mid-April, the Mayne Pharma share price has struggled in 2021. Including today’s price action, shares in the pharmaceutical company are down more than 7% year-to-date.

At the time of writing, the Mayne share price is trading 6% lower for the day at 31.5 cents.

The post Mayne Pharma (ASX:MYX) share price drops on class action appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Leading broker slaps $89 target on CBA (ASX:CBA) share price
Why Afterpay, Bellevue Gold, Pilbara Minerals, & Zip are charging higher

Here’s why the Vital Metals (ASX:VML) share price is flying higher today
Here’s why the Zip (ASX:Z1P) share price is rocketing 8%
What’s driving the PointsBet (ASX:PBH) share price sharply lower?

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!